Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kelsey S. Lau-Min"'
Autor:
Kelsey S. Lau-Min, Lisa A. Varughese, Maria N. Nelson, Christine Cambareri, Nandi J. Reddy, Randall A. Oyer, Ursina R. Teitelbaum, Sony Tuteja
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Pharmacogenetic (PGx) testing for germline variants in the DPYD and UGT1A1 genes can be used to guide fluoropyrimidine and irinotecan dosing, respectively. Despite the known association between PGx variants and chemotherapy toxici
Externí odkaz:
https://doaj.org/article/8056029013234379a4bfba137431d963
Autor:
Lisa A. Varughese, Madhuri Bhupathiraju, Glenda Hoffecker, Shannon Terek, Margaret Harr, Hakon Hakonarson, Christine Cambareri, Jessica Marini, Jeffrey Landgraf, Jinbo Chen, Genevieve Kanter, Kelsey S. Lau-Min, Ryan C. Massa, Nevena Damjanov, Nandi J. Reddy, Randall A. Oyer, Ursina R. Teitelbaum, Sony Tuteja
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline DPYD and UGT1A1 variants associated with red
Externí odkaz:
https://doaj.org/article/9516907262044f3197382352e2d55e3c
Autor:
Lisa A. Varughese, Kelsey S. Lau-Min, Ursina Teitelbaum, AnnaClaire Osei-Akoto, Nandi Reddy, Nevena Damjanov, Ryan Massa, Sony Tuteja
Publikováno v:
Journal of Clinical and Translational Science, Vol 5, Pp 103-104 (2021)
ABSTRACT IMPACT: The implementation of DPYD and UGT1A1 pharmacogenetic testing, a promising tool of precision medicine, translates evidence-based research into clinical oncology practice with personalized dosing to better predict interpatient variabi
Externí odkaz:
https://doaj.org/article/858d95dc207748dfbafd6f87c8a6f07c
Autor:
Kelsey S. Lau-Min, Danielle McKenna, Stephanie Byers Asher, Tanya Bardakjian, Colin Wollack, Joseph Bleznuck, Daniel Biros, Arravinth Anantharajah, Dana F. Clark, Courtney Condit, Jessica E. Ebrahimzadeh, Jessica M. Long, Jacquelyn Powers, Anna Raper, Anna Schoenbaum, Michael Feldman, Lauren Steinfeld, Sony Tuteja, Christine VanZandbergen, Susan M. Domchek, Marylyn D. Ritchie, Jeffrey Landgraf, Jessica Chen, Katherine L. Nathanson
Publikováno v:
Genetics in Medicine. 24:2338-2350
Integrating genomic data into the electronic health record (EHR) is key for optimally delivering genomic medicine.The PennChart Genomics Initiative (PGI) at the University of Pennsylvania is a multidisciplinary collaborative that has successfully lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::220196df29df1e5836b4173cbac6eec9
https://doi.org/10.1016/j.gim.2022.08.009
https://doi.org/10.1016/j.gim.2022.08.009
Publikováno v:
J Natl Compr Canc Netw
Background: Germline genetic testing (GT) for BRCA1/2 is instrumental in identifying patients with breast and ovarian cancers who are eligible for PARP inhibitors (PARPi). Little is known about recent trends and determinants of GT since PARPi were ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26293c4f4d8e964991358629df668b7e
https://europepmc.org/articles/PMC10256435/
https://europepmc.org/articles/PMC10256435/
Publikováno v:
Cancer
Timely targeted treatment initiation can be challenging because additional biomarker testing is needed for eligibility. The authors hypothesized that timely targeted treatment improves survival relative to nontimely initiation in metastatic HER2+ gas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b22010e4c4630d74cd7f4bb3770ad5d
https://doi.org/10.1002/cncr.34117
https://doi.org/10.1002/cncr.34117
Autor:
Michael Feldman, Jeffrey Landgraf, Sony Tuteja, Virginia Speare, Marylyn D. Ritchie, Katherine L. Nathanson, Lisa A. Varughese, Jessica A. Chen, Susan M. Domchek, Steven Joffe, Christine VanZandbergen, Kelsey S. Lau-Min, Stephanie Byers Asher
Publikováno v:
Genetics in Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26e1ba3e2db20a7729e2428efb675831
http://europepmc.org/articles/PMC8026392
http://europepmc.org/articles/PMC8026392
Autor:
Kelsey S. Lau-Min, Jessica Marini, Nishant Shah, Donna Pucci, Abigail Blauch, Christine Cambareri, Bethany Mooney, Caleb Johnston, Ryan P. Schumacher, Kyle White, Peter Edward Gabriel, Roy Rosin, Linda A. Jacobs, Lawrence N. Shulman
Publikováno v:
Journal of Clinical Oncology. 40:424-424
424 Background: Capecitabine (cape), an oral chemotherapy, is the treatment backbone for many GI cancers. Its complex dosing and narrow therapeutic index make medication adherence and toxicity management crucial for quality patient care. Methods: We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::243b0cf21e31b55cb3ad951e93e14c14
https://doi.org/10.1200/jco.2022.40.28_suppl.424
https://doi.org/10.1200/jco.2022.40.28_suppl.424
Publikováno v:
Journal of Clinical Oncology. 40:10583-10583
10583 Background: Germline BRCA1/2 testing (GT) is instrumental in identifying patients with breast and ovarian cancer who may be eligible for biomarker-driven poly ADP ribose polymerase inhibitor (PARPi) therapy. Little is known about recent trends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a054437ee6a81e65ed4bb75b7834a368
https://doi.org/10.1200/jco.2022.40.16_suppl.10583
https://doi.org/10.1200/jco.2022.40.16_suppl.10583
Autor:
Ronac Mamtani, Kelsey S. Lau-Min, Jennifer R. Eads, Xiaoliang Wang, Kelly D. Getz, Yimei Li, Neal J. Meropol
Publikováno v:
Cancer
Background Anti human epidermal growth factor receptor 2 (anti-HER2) therapy with trastuzumab improves overall survival in patients with advanced, HER2-positive gastroesophageal adenocarcinoma (GEA) and is now incorporated into national guidelines. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::258f1200692efb511e119fe19d2e3734
https://europepmc.org/articles/PMC8249344/
https://europepmc.org/articles/PMC8249344/